HCV Archives – Page 4 of 30 – Treatment Action Group

Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies

October 27, 2022
Dorrit Walsh

On November 16, 2022, please join TAG, INPUD and AfroCAB for our webinar “Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies” at 8:00 a.m. EST / 02:00 p.m. CET / 05:30 IST.

Towards Pandemic Equity: Lessons from 30 Years of Syndemic Activism

October 19, 2022
Dorrit Walsh

By Mike Frick and Mark Harrington The articles in this 30th anniversary issue of TAGline grapple with “pandemic equity,” an increasingly common catchphrase in global health. COVID-19 has shown that “equity,” like its cousins “justice,” “fairness,” and “equality,” is one…

The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation

September 21, 2022
Dorrit Walsh

As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.

Treatment Action Group Statement on Retirement of Dr. Anthony S. Fauci

August 23, 2022
Dorrit Walsh

Treatment Action Group (TAG) meets with sadness the announcement by Dr. Anthony S. Fauci of his retirement as Director of the National Institute of Allergy and Infectious Diseases (NIAID), Chief of the NIAID Laboratory of Immunoregulation, and Chief Medical Advisor to President Biden, effective in December 2022.

Treatment Action Group Adds Three New Board Members

August 23, 2022
Dorrit Walsh

As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.

LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available

August 1, 2022
Dorrit Walsh

Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.

LAT CAB Video Presentation

July 28, 2022
Dorrit Walsh

This video, offered here in English, French, and Spanish, was made to be shown at the AfroCAB booth at the 24th International AIDS Conference.

Cover of Pipeline Report 2022. Black cover with grey type and decorative bright green lines

2022 Pipeline Report

July 24, 2022
Dorrit Walsh

Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).

Research in Action Awards 2022

July 8, 2022
Dorrit Walsh

Save the date for Tuesday, November 16, 2021! TAG’s 2021 Research in Action Awards will honor some of the best and brightest activists, scientists, and leaders in the fight to end HIV, tuberculosis, and hepatitis C across the U.S. and around the world. This year we’ll once again gather virtually to ensure this year’s event is safe and open for participation to our allies and friends across the U.S. and world.

Treatment Action Group Statement on NYC DOHMH Monkeypox Vaccination Announcement

June 23, 2022
Dorrit Walsh

In response to this morning's announcement by the New York City Department of Health and Mental Hygiene (NYC DOHMH) that the DOHMH would open a temporary monkeypox vaccination clinic at the Chelsea Sexual Health Clinic in New York, Treatment Action Group's Executive Director, Mark Harrington, and TAG HIV Project Director Riko A. Boone, MSW, MPH, MA, said: